Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Boehringer Ingelheim
Johnson and Johnson
Express Scripts
Harvard Business School

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

VARITHENA Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Varithena, and when can generic versions of Varithena launch?

Varithena is a drug marketed by Provensis and is included in one NDA. There are fourteen patents protecting this drug.

This drug has one hundred and eighty-six patent family members in thirty-nine countries.

The generic ingredient in VARITHENA is polidocanol. Two suppliers are listed for this compound. Additional details are available on the polidocanol profile page.

Drug patent expirations by year for VARITHENA
Drug Prices for VARITHENA

See drug prices for VARITHENA

Recent Clinical Trials for VARITHENA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
OhioHealthN/A
BTG International Inc.N/A
BTG International Inc.Phase 4

See all VARITHENA clinical trials

Synonyms for VARITHENA
2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol
3,6,9,12,15,18,21,24,27-Nonaoxanonatriacontan-1-ol
3055-99-0
73579-17-6
9043-30-5
95297-49-7
AC1LCVC1
AEO-9
Aethoxy-sklerol
AKOS028108701
AN-6543
API0005051
Asclera
C12E9
C13493
CAS-3055-99-0
CHEBI:46859
CHEMBL1231723
CTK1C2495
DB06811
Detergent Screening Solution 23/Fluka kit no 66317
DODECYL NONA ETHYLENE GLYCOL ETHER
Dodecyl nonaethylene glycol ether
Dodecylnonaglycol
Dodecylnonaoxyethylene glycol monoether
DSSTox_CID_19721
DSSTox_GSID_39721
DSSTox_RID_79436
DTXSID5039721
EINECS 221-284-4
genapol X 080
genapol X-080
Genapol X080
GK9185
J-018016
KS-00000Y0K
laureth-9
Macrogol 9 lauryl ether
MFCD00043375
MFCD00163738
MolPort-003-935-762
NCGC00166290-01
NCGC00166290-02
NCGC00166290-03
Nonaethylene glycol monododecyl ether
Nonaethylene glycol monododecyl ether, nonionic surfactant
nonaethylene glycol monolauryl ether
Nonaethyleneglycol monododecyl ether 1 mM solution
Nonaethyleneglycol monododecyl ether solution
Oligoethylene glycol monoalkyl ether
ONJQDTZCDSESIW-UHFFFAOYSA-N
PEG-9 lauryl ether
POELE
Polidocanol
Polidocanol [INN:DCF:JAN]
Poly(oxy-1,2-ethanediyl),a-isotridecyl-w-hydroxy-
Polydocanol
POLYDOCANOL; THESIT
Polyethylene glycol 450 lauryl ether
Polyethylene glycol monoalkyl ether
Polyethylene glycol monododecyl ether (average polymer, n = 9; nonaethylene glycol monododecyl ether)
Polyethylene glycol monododecyl ether (average polymer, n = 9)
Polyethylene glycol monoisotridecyl ether
Polyoxyethylen-9-laurylether
Polyoxyethylene (9) lauryl ether
Polyoxyethylene 9 lauryl ether
Polyoxyl 9 lauryl ether
SCHEMBL25580
SR-01000944476
SR-01000944476-1
Tox21_112394
Tox21_112394_1
ZINC8214662

US Patents and Regulatory Information for VARITHENA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-002 Dec 21, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
Provensis VARITHENA polidocanol SOLUTION;INTRAVENOUS 205098-001 Nov 25, 2013 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
McKesson
AstraZeneca
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.